Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Developmental therapeutics updates to look at for at ASCO 2021

Filip Janku, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares exciting updates being presented at the ASCO Annual Meeting 2021 in the field of developmental therapeutics. Dr Janku’s highlights include first-in-human study data on RBN-2397, an oral PARP7 inhibitor, in patients with advanced solid tumors; findings from a trial of a selective glutaminase-1 inhibitor; and efficacy and safety data of zenocutuzumab in tumors with NRG1 fusions. Dr Janku also highlights the promise of basket studies in precision oncology, notably the MyPathway HER2 basket study (NCT02091141) which will share interesting data on pertuzumab and trastuzumab in HER2-positive advanced solid tumors. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Filip Janku, MD, PhD has research support from Astex, Novartis, BioMed Valley Discoveries, Fore Bio, Deciphera, Bristol-Myers Squibb, Asana, Ideaya Biosciences, Sanofi, Merck, F-star, JSI Innopharm, Bioxcel, Lilly, Bicara, PureTech Health, FujiFilm Pharmaceuticals, Sotio, Synlogic, NextCure, Hutchinson Medipharma; is on the Scientific Advisory Boards of Ideaya Biosciences, Synlogic, Sotio, Puretech Health, Deciphera, Crown Bioscience, Asana, Fore Bio, Novartis, Bicara, and PegaOne; is a paid consultant for Mersana Therapeutics, Flame Bio, Cardiff Oncology, MedinCell, and Immunomet; and has ownership interests in Cardiff Oncology.